Treatment

Document Overview

Design and created by Guideline Central in participation with the American Society of Clinical Oncology.

Systemic Therapy for Advanced Hepatocellular Carcinoma

American Society of Clinical Oncology

Publication Date: Mar 18, 2024

Page Last Updated: May 5, 2026

Recommendation Grading

Type		Benefit/harm		Evidence Quality		Strength of Recommendation
EB	Evidence-based	B	Benefits outweigh harms	H	High	Strong
FC	Formal consensus	H	Harms outweigh benefits	I	Intermediate	Moderate
IC	Informal consensus	B/H	Relative balance of benefits and harms	L	Low	Weak
IC	Informal consensus	B/H	Relative balance of benefits and harms	Ins	Insufficient	Weak

Document Overview

Document Title: Systemic Therapy for Advanced Hepatocellular Carcinoma

Authoring Society: American Society of Clinical Oncology

Document Publication Date: Mar 18, 2024

Page Last Reviewed/Updated: May 5, 2026

Document Type: Guideline

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: ascopubs.org/doi/10.1200/JCO.23.02745

Source Citation: John D. Gordan, MD, PhD; Erin B. Kennedy, MHSc; Ghassan K. Abou-Alfa, MD, MBA, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2024 March 19. doi: JCO.23.02745

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Document Objectives: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).

Scope: Management, Treatment

Diseases/Conditions (MeSH)

D006528 - Carcinoma, Hepatocellular

Keywords: child-pugh class A liver disease, hepatocellular carcinoma, liver diseases

Target Patient Population: Patients with advanced hepatocellular carcinoma.

Inclusion Criteria: Male, Female, Adult, Older Adult

Health Care Settings: Ambulatory, Emergency Care, Home Health, Hospice, Hospital, Long Term Care

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant, Social Worker

Recommendation Development Processes & Methodology

PICO Questions

What are the preferred treatment options for first-line systemic therapy for patients with advanced hepatocellular carcinoma?
What are the preferred treatment options for second- or later-line therapy for patients with advanced hepatocellular carcinoma?

Supplemental Methodology Resources: Data Supplement Evidence Tables

Number of Source Documents: 122

Literature Search Start Date: Friday, May 15, 2020

Literature Search End Date: Thursday, October 5, 2023

Includes peer/external review process?: Yes

Includes public comment process?: Yes

Methodologist involvement?: Yes

Patient involvement?: No

Includes multi-disciplinary group?: Yes

Includes systematic review?: Yes

Grades quality of strength of evidence?: Yes

Grades quality of strength of recommendation?: Yes

Discloses funding source?: Yes

Discloses conflicts of interest?: Yes

Includes benefits/harms analysis with recommendations?: Yes

Systemic Therapy for Advanced Hepatocellular Carcinoma

Treatment

First-line Therapy

Recommendation 1.1

Recommendation 1.2

Second-line Therapy

Recommendation 2.1

Recommendation 2.2

Recommendation 2.3

Third-line Therapy

Recommendation 3.1

Child-Pugh class B

Recommendation 4.1

Recommendation Grading

Document Overview

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Recommendation Development Processes & Methodology